Document:

Intellectual Property Security Agreement

 Exhibit 10.2 
 INTELLECTUAL PROPERTY SECURITY AGREEMENT 
 This Intellectual Property Security Agreement (this “IP Agreement”) is made as of the 15th day of April, 2008 by
and between CV THERAPEUTICS, INC., a Delaware corporation (“Grantor”), and TPG-AXON ROYALTY TRUST, a trust established under the laws of the Republic of Ireland (“Secured Party”).

 RECITALS 
 Grantor has agreed to sell the right to receive certain payments to Secured Party (the “Royalty”) based on sales of Regadenoson, the chemical name and structure of which are set forth on Exhibit A attached
hereto (“Regadenoson”), pursuant to a certain Asset Sale and Purchase Agreement dated as of April 10, 2008 between Grantor and Secured Party, as amended from time to time (as amended, the “Purchase
Agreement”). The closing of the transactions contemplated by the Purchase Agreement is contingent upon the execution and delivery of this IP Agreement. Secured Party is willing to enter into the Purchase Agreement with Grantor, but only
upon the condition, among others, that Grantor shall grant to Secured Party a security interest in certain patents, patent applications and other assets, to secure the payment and performance of Grantor’s obligations under the Purchase
Agreement and the other Transaction Documents. Defined terms used but not defined herein shall have the same meanings as in the Purchase Agreement. 
 AGREEMENT 
 NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby
acknowledged and intending to be legally bound, Grantor hereby represents, warrants, covenants and agrees as follows: 
 Effective as
of the Closing Date, Grantor does hereby grant to Secured Party a continuing security interest of first priority in all of Grantor’s right, title and interest in, to and under the following registered and unregistered intellectual property
collateral, whether now or hereafter existing, and any and all proceeds thereof, as security for the prompt and complete payment and performance of all of Grantor’s obligations now or hereafter existing under the Purchase Agreement, this IP
Agreement, and the other Transaction Documents (all of which shall collectively be called the “Intellectual Property Collateral”): 
 (a) All Licensed Patents in the Territory set forth on Exhibit B attached hereto and any Licensed Patents in the Territory
issued after the date of this Agreement (the “Patents”); 
 (b) All Licensed Know-How in the
Territory; 
 (c) All licenses or other rights to use any of the Licensed Patents in the Territory, including, without
limitation, the licenses under the Astellas Agreement (collectively, the “Licenses”); 
 (d) Any and
all claims and causes of action for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the
intellectual property rights identified above; 
  

 1. 

 (e) All amendments, extensions, renewals and extensions of any of the Patents or the
Licenses; 
 (f) The CVT Royalty Interest; and 
 (g) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty
payable in respect of any of the foregoing. 
 This security interest is granted in conjunction with the security interest granted to Secured
Party under the Purchase Agreement. Upon the occurrence and during the continuance of a CVT Event of Default, Secured Party shall have the right to exercise all the remedies of a secured party under the Code. Grantor will pay any expenses (including
reasonable attorney’s fees) incurred by Secured Party in connection with the exercise of any of Secured Party’s rights hereunder, including without limitation any expense incurred in disposing of the Intellectual Property Collateral. All
of Secured Party’s rights and remedies with respect to the Intellectual Property Collateral shall be cumulative. 
 Grantor represents
and warrants that Exhibit B attached hereto sets forth any and all intellectual property rights in connection with which Grantor has registered or filed a patent application with the United States Patent and Trademark Office with respect to
Regadenoson. 
 The provisions of this IP Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns. Neither this IP Agreement nor any rights or obligations hereunder may be assigned, sold or otherwise disposed of or transferred in whole or in part by any party, by operation of law or otherwise, without the prior
written consent of the other party, except in accordance with the terms of Section 9.6 of the Purchase Agreement in the same manner as a permitted assignment of some or all of a party’s rights and/or obligations under the Purchase
Agreement. 
 This IP Agreement shall be governed by and construed, interpreted and enforced in accordance with the laws of the State of New
York, as applied to agreements executed and performed entirely in New York, without giving effect to the principles of conflicts of law thereof other than Section 5-1401 of the General Obligations Law of the State of New York. 
 [Signature pages follow.] 
  

 2. 

 IN WITNESS WHEREOF, the parties have caused this IP
Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above. 
  

									
	GRANTOR:	 		 	SECURED PARTY:
			
	CV THERAPEUTICS, INC.	 		 	PFPC BANK LIMITED
		 		 	in its sole capacity as trustee, and on behalf, of
		 		 	TPG-AXON ROYALTY TRUST,
	By: 	 	Louis G. Lange	 		 	a trust established under the laws of the Republic of Ireland
		 		 		 	
	Print Name: 	 	Louis G. Lange, M.D., Ph.D.	 		 	
	Title: 	 	Chairman of the Board and Chief	 		 	
		 	Executive Officer	 		 	
		 		 		 	By:	 	Paul Halley
		 		 		 	Name: 	 	Paul Halley
		 		 		 	Title:	 	Head of Trustee and Custodial Services

  

 3. 

 EXHIBIT A 
 REGADENOSON 
 

 
 known as (1-{9-[(4S, 2R, 3R,
5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, and identified by the Chemical Abstracts Service Registry Number 313348-27-5. 
  

 4. 

 EXHIBIT B 
 LICENSED PATENTS 
  

							
	 Country
	  	 Application No.
	  	 Patent / Publication No.
	  	 Title

	 Patent Cooperation
 Treaty (“PCT”)
	  	PCT/US00/40281	  	WO 00/78779 A2	  	N-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 PCT
	  	PCT/US00/17095	  	WO 00/78778 A2	  	C-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 PCT
	  	PCT/US01/05831	  	WO 01/62979 A2	  	METHOD OF IDENTIFYING PARTIAL AGONISTS OF THE A2A RECEPTOR
				
	 PCT
	  	PCT/US03/23511	  	WO 2004/011010 A1	  	MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS
				
	 PCT
	  	PCT/US04/002304	  	WO 2005/082379 A1	  	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS
				
	 PCT
	  	PCT/US2005/037368	  	WO 2006/044856 A2	  	USE OF A2A ADENOSINE RECEPTOR AGONISTS
				
	 PCT
	  	PCT/US2007/003022	  	WO 2007/092372 A1	  	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS
				
	 United States
	  	US 09/338,185	  	US 6,403,567 B1	  	N-PYRAZOLE A2A ADENOSINE RECEPTOR AGONISTS
				
	 United States
	  	US 10/018,446	  	US 6,642,210 B1	  	2-(N-PYRAZOLO) ADENOSINES WITH APPLICATION AS ADENOSINE A2A RECEPTOR
AGONISTS
				
	 United States
	  	US 10/652,378	  	US 7,183,264 B2	  	N-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 United States
	  	US 11/252,760	  	US 7,144,872 B2	  	N-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 United States
	  	US 11/588,834	  	US 2007/0203090 A1	  	N-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 United States
	  	US 09/338,327	  	US 6,214,807 B1	  	C-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 United States
	  	US 09/812,176	  	US 6,855,818 B2	  	C-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 United States
	  	US 10/018,758	  	US 6,770,634 B1	  	C-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 United States
	  	US 10/813,535	  	US 7,109,180 B2	  	C-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 United States
	  	US 11/522,120	  	US 2007/0207978 A1	  	C-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 United States
	  	US 11/070,768	  	US 2005/0175535 A1	  	MYOCARDIAL PERFUSION IMAGING METHOD
				
	 United States
	  	US 10/629,368	  	US 2004/0064039 A1	  	MYOCARDIAL PERFUSION IMAGING METHOD
				
	 United States
	  	US 10/766,403	  	US 2005/0020915 A1	  	MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS
				
	 United States
	  	US 11/253,322	  	US 2006/0084625 A1	  	USE OF A2A ADENOSINE RECEPTOR AGONISTS
				
	 United States
	  	US 11/701,699	  	US 2007/0265445 A1	  	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS
				
	 United States
	  	US 11/750,295	  	US 2007/0225247 A1	  	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS

  

 5. 

							
	 Country
	  	 Application No.
	  	 Patent / Publication No.
	  	 Title

	 United States
	  	US 11/766,964	  	US 2007/0299089 A1	  	USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA
				
	 United States
	  	US 11/848,743	  	Not published	  	METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS
				
	 United States
	  	US 11/864,437	  	Not published	  	METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE
				
	 United States
	  	US 11/969,047	  	Not published	  	MYOCARDIAL PERFUSION IMAGING
				
	 Canada
	  	CA2000002377746	  	CA2377746 C	  	N-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 Canada
	  	CA2000002375430	  	CA2375430 C	  	C-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 Canada
	  	CA2001002439222	  	CA2439222AA	  	METHOD OF IDENTIFYING PARTIAL AGONISTS OF THE A2A RECEPTOR
				
	 Canada
	  	CA2003002492855	  	CA2492855AA	  	MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS
				
	 Canada
	  	CA2004002554169	  	CA2554169AA	  	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS
				
	 Canada
	  	CA2005002583185	  	CA2583185AA	  	USE OF A2A ADENOSINE RECEPTOR AGONISTS
				
	 Mexico
	  	MX2001PA0013325	  	MX244944	  	N-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 Mexico
	  	MX2001PA0013350	  	MX245023	  	C-PYRAZOLE A2A RECEPTOR AGONISTS
				
	 Mexico
	  	MX2005PA0001123	  	Only abstract published	  	MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS
				
	 Mexico
	  	MX2006PA008521	  	Only abstract published	  	MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS
				
	 Mexico
	  	MX2007PA004749	  	Only abstract published	  	USE OF A2A ADENOSINE RECEPTOR AGONISTS

  

 6.Employment Agreement

 Exhibit 10.1 
 EMPLOYMENT AGREEMENT 
 This Employment Agreement, dated as of May 13, 2008 (this
“Agreement”), is between Orchid Cellmark Inc., a Delaware corporation (the “Company”), and Mr. Jeffrey S. Boschwitz, who resides at the address listed at the bottom of this Agreement (“Employee”). This
Agreement is intended to confirm the understanding between the Company and Employee with respect to Employee’s future employment by the Company. In consideration of the mutual promises and covenants contained in this Agreement, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the parties have agreed as follows: 
  

	 	1.	Employment. 

 (a) Title and Duties. Subject
to the terms and conditions of this Agreement, the Company will employ Employee, and Employee will be employed by the Company, as Vice President, North America Marketing and Sales, reporting to the Chief Executive Officer, provided, that
Employee’s reporting relationship may change from time to time at the sole discretion of the Company. Employee will have the responsibilities, duties and authority commensurate with said positions. Employee will also perform such other services
of an employment nature for the Company as may be assigned to Employee from time to time by the Chief Executive Officer. 
 (b) Devotion to
Duties. For so long as Employee is employed hereunder, Employee will devote substantially all of Employee’s business time and energies to the business and affairs of the Company, provided, that nothing contained in this
Section 1(b) will be deemed to prevent or limit Employee’s right to manage Employee’s personal investments on Employee’s own personal time, including, without limitation, the right to make passive investments in the securities of
(i) any entity which Employee does not control, directly or indirectly, and which does not compete with the Company, or (ii) any publicly held entity so long as Employee’s aggregate direct and indirect interest does not exceed three
percent (3%) of the issued and outstanding securities of any class of securities of such publicly held entity. 
 (c) Purchase of
Equity Interest. Subject to the Company’s policy regarding black-out periods and any applicable securities laws, Employee agrees to purchase in the open-market within six (6) months after the Commencement Date (as defined below) common
stock of the Company for an aggregate purchase price of not less than $10,000. In order to assist Employee in fulfilling the foregoing obligation, the Company will, upon Employee’s request at a time when Employee does not have material
non-public information, provide reasonable assistance to Employee in establishing a Prearranged Trading Plan pursuant to SEC Rule 10b5-1, under which Employee may make prior arrangements to trade equity of the Company. 

	 	2.	Term of Employment. 

 (a) Term. Subject to
the terms hereof, Employee’s employment hereunder will commence on May 21, 2008 (the “Commencement Date”) and will continue until May 21, 2011 (the “Initial Term”); provided, that Employee’s employment
hereunder will be automatically extended for additional consecutive periods of one (1) year (each, a “Subsequent Term”) unless either Employee or the Company has given written notice to the other that such automatic extension will not
occur (a “Non-Renewal Notice”), which notice must be given no less than three (3) months prior to the end of the relevant Initial Term or Subsequent Term. The Initial Term and any Subsequent Terms are referred to herein as the
“Term.” 
 (b) Termination. Notwithstanding anything else contained in this Agreement, Employee’s employment hereunder
will terminate upon the earliest to occur of the following: 
 (i) Death. Employee’s death, which termination shall be effective
immediately; 
 (ii) Termination by the Company. 
 (A) Written notice by the Company to Employee that Employee’s employment is being terminated as a result of Employee’s
incapacity or inability to further perform Employee’s duties and responsibilities as contemplated herein for ninety (90) days or more within any six (6) month period, or because Employee’s physical or mental health has become so
impaired as to make it impossible or impractical for Employee to perform Employee’s duties and responsibilities contemplated herein (it being understood that the determination of Employee’s physical or mental health will be determined by a
medical expert appointed by mutual agreement between the Company and Employee) (such condition hereafter referred to as the “Disability”), which termination shall be effective on the date of such notice; 
 (B) Written notice by the Company to Employee that Employee’s employment is being terminated for Cause (as defined below), which
termination shall be effective on the date of such notice; or 
 (C) Written notice by the Company to Employee that
Employee’s employment is being terminated without Cause, which termination shall be effective on the date of such notice; or 
 (iii)
Termination by Employee. Written notice by Employee to the Company that Employee is terminating Employee’s employment for any reason, which termination shall be effective thirty (30) days after the date of such notice; or

 (iv) End of Term. Conclusion of the Term, provided that either the Company or Employee has given a timely Non-Renewal Notice.

  

 2 

 Notwithstanding anything in this Section 2(b), the Company may at any point terminate
Employee’s employment for Cause prior to the effective date of any other termination contemplated hereunder. 
 (c) Definition of
“Cause”. For purposes of this Agreement, “Cause” shall mean that Employee has (i) intentionally committed an act or omission that materially harms the Company; (ii) been grossly negligent in performance of
Employee’s duties to the Company; (iii) committed an act of moral turpitude; (iv) committed an act of fraud or material dishonesty in discharging Employee’s duties to the Company; (v) breached any material provision of this
Agreement or any nondisclosure, non-competition or other agreement (including the Intellectual Property, Confidentiality, Non-Competition and Non-Solicitation Agreement attached hereto as Exhibit A), between Employee and the Company, as all
of the foregoing may be amended from time to time, that results in material harm to the Company; or (vi) breached any provision of any code of conduct or ethics policy in effect at the Company, as all of the foregoing may be amended from time
to time; provided, that in the case of subparagraph (ii) where such gross negligence and the effects of such gross negligence are capable of remedy by the Employee, there shall be no Cause unless the Company provides Employee with
written notice reasonably detailing the purported basis for the Cause and Employee fails to remedy the effects of such gross negligence within thirty (30) days after Employee’s receipt of such notice. 
 (d) Definition of “Change of Control”. For purposes of this Agreement, a “Change of Control” shall occur on the date that
either of the following occurs: (i) any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act),
directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company’s then outstanding voting securities (excluding for this purpose the Company or its
affiliated entities or any employee benefit plan of the Company); or (ii) a merger or consolidation of the Company whether or not approved by the Board, other than a merger or consolidation which would result in the voting securities of the
Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least fifty percent (50%) of the
total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation outstanding immediately after such merger or consolidation, or the consummation of an agreement for the sale or
disposition of the Company of all or substantially all of the Company’s assets. “Substantially all of the Company’s assets” shall be deemed to include the assets of all business units and/or divisions of the Company and all of
its affiliated entities. In all respects, the definition of “Change of Control” shall be interpreted to comply with Section 409A of the Internal Revenue Code of 1986, as amended, and any successor statute, regulation and guidance
thereto. 
  

 3 

	 	3.	Compensation. 

 (a) Base Salary. While
Employee is employed hereunder, the Company will pay Employee a base salary at the gross annual rate of $230,000 (the “Base Salary”). The Chief Executive Officer shall review Employee’s Base Salary on at least an annual basis, with
the first such review to be conducted in April 2009, and the Base Salary may be adjusted at the sole discretion of the Chief Executive Officer or the Board of Directors (the “Board”) or its designee. The Base Salary will be payable in
accordance with the Company’s payroll practices as in effect from time to time. The Company will deduct from each such installment any amounts required by law to be deducted for employment related taxes and the like. 
 (b) Annual Bonus. Employee will also be eligible to receive an annual performance bonus in accordance with the Orchid Cellmark Inc. Incentive Bonus
Plan (or, if applicable, any successor plan). The award and amount of any annual performance bonus shall be determined by the Chief Executive Officer and the Compensation Committee of the Board (or its designee) and shall be primarily based on
Employee’s performance and the overall performance of the Company, measured against goals that are approved by the Chief Executive Officer and the Compensation Committee. For 2008 the Employee’s goals will be based on the 2008 Annual
Company goals and, in particular, those goals pertaining to the Marketing and Sales Department. The bonus target for each year will be twenty-five percent (25%) of Employee’s Base Salary in effect at the end of the calendar year to which
it relates, and the amount of any annual performance bonus for 2008 shall be pro-rated based on the number of calendar days in 2008 during which the Company employs Employee as an Employee. The Employee shall use reasonable efforts to submit
proposed performance goals for 2008 within three months of the Commencement Date, to be reviewed and approved by the Chief Executive Officer. For subsequent years, the Employee shall submit proposed performance goals to be reviewed and approved by
the Chief Executive Officer and the Compensation Committee of the Board in their sole discretion, no later than March 31 of the year to which the goals relate. 
 (c) Equity Compensation. 
 (i) Stock Options. The Company will grant to
Employee non-qualified stock options to purchase Fifty Thousand (50,000) shares of the common stock of the Company at an exercise price equal to the fair market value of such stock at the close of market on May 20, 2008 (the “Grant
Date”), which options will vest monthly in forty-eight (48) equal installments over the four (4) years following the Grant Date, provided that Employee remains employed by the Company on the applicable date and, except as otherwise
provided in this Agreement, subject to such other terms and conditions as set forth in the Company’s standard form of option agreement. 
  

 4 

 (ii) Effect of Change of Control. Notwithstanding anything herein to the contrary,
in the event of a Change of Control, all stock options held by Employee which have not previously vested shall vest and become fully exercisable upon the Change of Control. 
 (iii) Stock Plan. The grant contemplated by 3(c)(i) shall be subject in all respects to the terms and conditions of the Orchid
BioSciences, Inc. 2005 Amended and Restated Stock Plan or such other plan as may be in effect at the time of grant. 
 (d) Fringe
Benefits. Employee shall be entitled to participate in all employee benefit, welfare and other plans, practices, policies and programs and fringe benefits of the Company on a basis no less favorable than those provided to other similarly
situated executives of the Company at the Vice President level. 
 (e) Vacation. Employee will be entitled to accrue up to twenty
(20) vacation days and five (5) sick days per calendar year that Employee remains employed by the Company, subject to the terms of the Company’s vacation and sick leave policies, as they may be amended from time to time. All vacation
days will be taken at times mutually agreed upon by Employee and the Company and will be subject to the business needs of the Company. 
 (f)
Reimbursement of Expenses. The Company will reimburse Employee for all ordinary and reasonable documented out-of-pocket business expenses that are incurred by Employee in furtherance of the Company’s business in accordance with the
Company’s policies with respect thereto as in effect from time to time. 
  

	 	4.	Severance Compensation. 

 (a) Definition of
Accrued Obligations. For purposes of this Agreement, “Accrued Obligations” means (i) the portion of Employee’s Base Salary that has accrued prior to any termination of Employee’s employment with the Company and has not
yet been paid; (ii) an amount equal to the value of Employee’s accrued unused vacation days; and (iii) the amount of any reasonable documented out-of-pocket expenses properly incurred by Employee on behalf of the Company prior to any
such termination and not yet reimbursed. 
 (b) Termination due to Death or Disability. If Employee’s employment hereunder is
terminated due to Employee’s death or Disability, the Company will pay the Accrued Obligations to Employee’s estate promptly following the effective date of such termination. 
 (c) Termination for Cause, or at the Conclusion of the Term. If Employee’s employment hereunder is terminated by the Company for Cause, or if
Employee’s employment terminates as a result of the expiration of the Term, the Company will pay the Accrued Obligations to Employee promptly following the effective date of such termination and shall have no further obligations to Employee.

  

 5 

 (d) Termination without Cause. If Employee’s employment hereunder is terminated by the
Company without Cause, then: 
 (i) The Company will pay the Accrued Obligations to Employee promptly following the effective
date of such termination; 
 (ii) The Company will pay Employee an amount equal to six (6) months of his Base Salary in
effect as of the effective date of such termination, which amount will paid, at the Company’s sole discretion (i) in accordance with the Company’s usual payroll practices, (ii) in a lump sum payment, or (iii) no more than
four (4) lump sum payments, provided that payment(s) hereunder shall begin no later than one (1) month following the effective date of the termination and the entire amount shall be paid within six (6) months of the effective date of
such termination. 
 (e) Effect of Termination On Equity. In the event of termination of Employee’s employment, all options shall
terminate in accordance with the terms of Employee’s option agreements in effect at the time of such termination. 
 (f) Release of
Claims. The Company shall not be obligated to pay Employee any of the payments set forth in Section 4 unless and until Employee has executed a timely separation agreement containing a general release in favor of the Company, and the
agreement has by its terms become effective. 
 (g) No Other Payments or Benefits Owing. The payments and benefits set forth in this
Section 4 shall be the sole amounts owing to Employee upon termination of Employee’s employment for any reason. Employee shall not be eligible for any other payments, including but not limited to additional Base Salary payments, bonuses,
commissions, or other forms of compensation or benefits. The compensation and benefits set forth in this Section shall be the sole remedy, if any, available to the Employee in the event that he brings any claim against the Company for any claims
arising from or relating to the termination of his employment under this Agreement. 
  

	 	5.	Confidentiality, Non-Competition, etc. As an inducement to the Company to enter into this Agreement and for the specific consideration set forth herein, including
without limitation Employee’s Base Salary in Section 3(a), Employee agrees to sign and return to the Company the Intellectual Property, Confidentiality, Non-Competition and Non-Solicitation Agreement attached hereto as Exhibit A
concurrently with the execution of this Agreement. 

  

	 	6.	Property and Records. Upon termination of Employee’s employment hereunder for any reason or for no reason, Employee will promptly deliver to the Company any property of
the Company which may be in Employee’s possession, including blackberry-type devices, laptops, cell phones, products, materials, memoranda, notes, records, reports or other documents or photocopies of the same. 

  

 6 

	 	7.	General. 

 (a) Notices. Except as otherwise
specifically provided herein, any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by
overnight courier upon written verification of receipt; (iii) by telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon
verification of receipt. Notices to Employee shall be sent to the last known address in the Company’s records or such other address as Employee may specify in writing. Notices to the Company shall be sent to the Company’s Chief Executive
Officer or to such other Company representative as the Company may specify in writing. 
 (b) Entire Agreement. This Agreement,
together with Employee Agreement attached hereto and the any other agreements specifically referred to herein, embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all
prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement will affect, or be used to interpret,
change or restrict, the express terms and provisions of this Agreement. 
 (c) Modifications and Amendments. The terms and provisions
of this Agreement may be modified or amended only by written agreement executed by the parties hereto. 
 (d) Waivers and Consents. The
terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent will be deemed to be
or will constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent will be effective only in the specific instance and for the purpose for which it was given,
and will not constitute a continuing waiver or consent. 
 (e) Assignment. The Company may assign its rights and obligations hereunder
to any person or entity that succeeds to all or substantially all of the Company’s business or that aspect of the Company’s business in which Employee is principally involved. Employee may not assign Employee’s rights and obligations
under this Agreement without the prior written consent of the Company. 
 (f) Governing Law. This Agreement and the rights and
obligations of the parties hereunder will be construed in accordance with and governed by the law of the State of New Jersey. 
  

 7 

 (g) Arbitration. Any dispute arising out of this Agreement shall be resolved through final and
binding arbitration. The arbitration shall be conducted under the auspices of the American Arbitration Association (“AAA”) in accordance with the rules and procedures of AAA then in effect. The arbitration shall take place in the State of
New Jersey and shall be heard and decided by a single arbitrator. The decision and award of the arbitrator shall be final and binding. The prevailing party in any such arbitration shall be entitled to recover its reasonable costs and attorney’s
fees incurred in connection with the arbitration. 
 (h) Severability. The parties intend this Agreement to be enforced as written.
However, should any provisions of this Agreement be held by a court of law to be illegal, invalid or unenforceable, the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby.

 (i) Headings and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience of reference
only and will in no way modify or affect the meaning or construction of any of the terms or provisions hereof. 
  

	 	8.	Taxation. Except as specifically set forth in this Agreement, the Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit
arising under this Agreement, including but not limited to consequences related to Section 409A of the Internal Revenue Code, as amended. The Company and Employee agree that both will negotiate in good faith and jointly execute an amendment to
modify this Agreement to the extent necessary to comply with the requirements of Code Section 409A, or any successor statute, regulation and guidance thereto; provided, that no such amendment shall increase the total financial obligation
of the Company under this Agreement. 

  

	 	9.	Counterparts. This Agreement may be executed in two or more counterparts, and by different parties hereto on separate counterparts, each of which will be deemed an original,
but all of which together will constitute one and the same instrument. For all purposes a signature by fax shall be treated as an original. 

 REMAINDER OF PAGE INTENTIONALLY LEFT BLANK 
  

 8 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above. 
  

							
	Jeffrey S. Boschwitz	 		 	ORCHID CELLMARK INC.
				
	/s/ Jeffrey S. Boschwitz	 		 	By:	 	/s/ Thomas A. Bologna
	 Signature
 Address:
	 		 		 	 Name: Thomas A. Bologna
 Title: President &
CEO

  

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]